This article is more than 5 years old. Information may no longer be current.

EyeGate public stock offering expected to generate $10 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals announced the pricing of a public offering of common stock and warrants that is expected to generate about $10 million, according to a press release.

The underwritten public offering involves 1,176,470 shares of common stock and warrants to purchase up to 1,176,470 shares of common stock at a combined price of $8.50 per share of common stock and warrant to purchase one share of common stock.

Warrants have a per-share exercise price of $10.62 and expire 5 years after the date of issuance, the release said.

Gross proceeds to EyeGate from the offering are expected to total about $10 million, minus underwriting discounts, commissions and other related expenses.

EyeGate’s common stock will be listed on the Nasdaq Capital Market and will be listed under the ticker symbol EYEG; warrants will be listed under the ticker symbol EYEGW. Stocks and warrants are listed as of July 31.

Additionally, EyeGate has granted the underwriters a 45-day option to purchase up to 176,470 additional shares of common stock and/or warrants.

The offering is expected to close Aug. 5.